360 related articles for article (PubMed ID: 19940282)
1. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
[TBL] [Abstract][Full Text] [Related]
2. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Fung C; Sesso HD; Williams AM; Kerns SL; Monahan P; Abu Zaid M; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Kollmannsberger CK; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Lipshultz SE; Einhorn LH; Fossa SD; Travis LB;
J Clin Oncol; 2017 Apr; 35(11):1211-1222. PubMed ID: 28240972
[TBL] [Abstract][Full Text] [Related]
3. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
4. Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor.
Solheim O; Skalleberg J; Warncke T; Ørstavik K; Tropé C; Fosså SD
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):240-249. PubMed ID: 30289161
[TBL] [Abstract][Full Text] [Related]
5. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer.
Glendenning JL; Barbachano Y; Norman AR; Dearnaley DP; Horwich A; Huddart RA
Cancer; 2010 May; 116(10):2322-31. PubMed ID: 20225230
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
[TBL] [Abstract][Full Text] [Related]
7. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.
Miaskowski C; Mastick J; Paul SM; Abrams G; Cheung S; Sabes JH; Kober KM; Schumacher M; Conley YP; Topp K; Smoot B; Mausisa G; Mazor M; Wallhagen M; Levine JD
J Cancer Surviv; 2018 Apr; 12(2):234-245. PubMed ID: 29159795
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
[TBL] [Abstract][Full Text] [Related]
9. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
10. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
[TBL] [Abstract][Full Text] [Related]
12. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.
Sprauten M; Darrah TH; Peterson DR; Campbell ME; Hannigan RE; Cvancarova M; Beard C; Haugnes HS; Fosså SD; Oldenburg J; Travis LB
J Clin Oncol; 2012 Jan; 30(3):300-7. PubMed ID: 22184390
[TBL] [Abstract][Full Text] [Related]
13. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
Ardeshirrouhanifard S; Fossa SD; Huddart R; Monahan PO; Fung C; Song Y; Dolan ME; Feldman DR; Hamilton RJ; Vaughn D; Martin NE; Kollmannsberger C; Dinh P; Einhorn L; Frisina RD; Travis LB
Ear Hear; 2022; 43(3):794-807. PubMed ID: 35067571
[TBL] [Abstract][Full Text] [Related]
14. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study.
Oldenburg J; Kraggerud SM; Brydøy M; Cvancarova M; Lothe RA; Fossa SD
J Transl Med; 2007 Dec; 5():70. PubMed ID: 18162130
[TBL] [Abstract][Full Text] [Related]
15. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
16. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer.
Berger CC; Bokemeyer C; Schneider M; Kuczyk MA; Schmoll HJ
Eur J Cancer; 1995 Dec; 31A(13-14):2229-38. PubMed ID: 8652248
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.
Sanchez VA; Shuey MM; Dinh PC; Monahan PO; Fosså SD; Sesso HD; Dolan ME; Einhorn LH; Vaughn DJ; Martin NE; Feldman DR; Kroenke K; Fung C; Frisina RD; Travis LB
J Clin Oncol; 2023 Apr; 41(12):2211-2226. PubMed ID: 36626694
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
[TBL] [Abstract][Full Text] [Related]
19. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.
ArdeshirRouhaniFard S; Dinh PC; Monahan PO; Fossa SD; Huddart R; Fung C; Song Y; Feldman DR; Hamilton RJ; Vaughn DJ; Martin NE; Kollmannsberger C; Einhorn L; Kroenke K; Travis LB
Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1129-1138. PubMed ID: 33849970
[TBL] [Abstract][Full Text] [Related]
20. Paternity following treatment for testicular cancer.
Brydøy M; Fosså SD; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Dahl O
J Natl Cancer Inst; 2005 Nov; 97(21):1580-8. PubMed ID: 16264178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
